Blue Cross and Blue Shield of Texas policies

Search Blue Cross and Blue Shield of Texas's public medical, payment and drug policies by CPT or HCPCS code, keyword or policy number, with links to the payer's own documents. Links open the payer's own document; check its current version before relying on it.

Checking prior authorization for J3490? Open Blue Cross and Blue Shield of Texas’s official lists and confirm the member’s product there.

23 policies name J3490, those listing the fewest codes first. A policy that names a code may also list it as excluded.

Blue Cross and Blue Shield of Texas policies
PolicyDetailsCodesSource
Gene Therapy for Aromatic L-amino Acid Decarboxylase DeficiencyRX501.178 · Effective Nov 15, 2025 · Commercial, Medicaid3Original policy ↗
NusinersenRX501.086 · Effective Jan 1, 2026 · Commercial, Medicaid3Original policy ↗
Sublingual Immunotherapy as a Technique of Allergen-Specific TherapyMED206.006 · Commercial, Medicaid3Original policy ↗
Treatment of Congenital AthymiaRX501.139 · Effective Dec 15, 2025 · Commercial, Medicaid3Original policy ↗
Etranacogene dezaparvovec-drlbRX501.151 · Effective Jan 1, 2026 · Commercial, Medicaid4Original policy ↗
Human Growth Hormone (GH)RX501.040 · Effective Jan 1, 2026 · Commercial, Medicaid4Original policy ↗
MepolizumabRX501.080 · Commercial, Medicaid4Original policy ↗
Corneal Collagen Cross-LinkingOTH903.028 · Commercial, Medicaid5Original policy ↗
Esketamine Nasal SprayRX501.105 · Commercial, Medicaid5Original policy ↗
Rituximab and Biosimilars for Non-Oncologic IndicationsRX502.030 · Effective Jan 1, 2026 · Commercial, Medicaid5Original policy ↗
FDA - Drugs, Biologicals, Cellular and Gene TherapiesRX501.087 · Commercial, Medicaid6Original policy ↗
Drug-Eluting Sinus ImplantsSUR706.021 · Effective Jan 1, 2026 · Commercial, Medicaid7Original policy ↗
Eculizumab and Associated Biosimilar(s)RX501.066 · Commercial, Medicaid8Original policy ↗
Denosumab and Biosimilars for Non-Oncologic IndicationsRX501.140 · Commercial, Medicaid14Original policy ↗
Unlisted/Not Otherwise Classified (NOC) Coding PolicyRP035 · Effective Aug 14, 2026 · Commercial, Medicaid · TX14Original policy ↗
Ustekinumab and Associated BiosimilarsRX501.114 · Effective Jul 1, 2026 · Commercial, Medicaid15Original policy ↗
Blue Choice PPOSM and Blue High Performance Network® Provider ManualCommercial, Medicaid · TX16Original policy ↗
Enzyme-Replacement Therapy for Lysosomal Storage DisordersRX501.067 · Commercial, Medicaid20Original policy ↗
Treatment of HyperhidrosisMED201.014 · Commercial, Medicaid20Original policy ↗
Immunoglobulin TherapyRX504.003 · Commercial, Medicaid30Original policy ↗
Cosmetic and Reconstructive ProceduresSUR716.001 · Commercial, Medicaid62Original policy ↗
Oncology MedicationsRX502.061 · Effective Jul 1, 2026 · Commercial, Medicaid175Original policy ↗
Medical Policies Moving to MCG GuidelinesADM1001.036 · Commercial, Medicaid303Original policy ↗

Back to Blue Cross and Blue Shield of Texas · Blue Cross and Blue Shield of Texas prior authorization CPT list

Disclaimer

The information provided on this page is for general informational purposes only and does not constitute billing, coding, or reimbursement advice. Nothing on this page should be relied upon as a substitute for clinician assessment, professional billing guidance, or as a definitive statement of any payor's billing requirements or policies.

Payor agreements, fee schedules, and billing policies vary and are subject to change. Before submitting any claims related to maternity care services, including claims affected by the 2027 CPT code revisions, please consult the applicable payor agreements, coverage policies, and billing guidelines to confirm current requirements for their specific payor contracts.

Substrate makes no representation or warranty regarding the accuracy, completeness, or timeliness of the payor-specific information presented here. Providers are solely responsible for ensuring that all claims are submitted in accordance with applicable payor requirements, and Substrate assumes no liability for claim denials, underpayments, or other adverse outcomes arising from reliance on this information.